Literature DB >> 16969280

Induction immunosuppression.

Allan D Kirk.   

Abstract

Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general, these agents have been shown to reduce the rate of acute rejection. However, their use has not been clearly shown to improve long-term transplant outcomes. This overview will review the biological basis for induction immunosuppression and the mechanisms of action of those specialized induction agents currently in clinical use. Clinical trials investigating induction regimens will be evaluated, and an individualized approach to the use of induction immunosuppressants will be presented.

Mesh:

Substances:

Year:  2006        PMID: 16969280     DOI: 10.1097/01.tp.0000234905.56926.7f

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  29 in total

Review 1.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

2.  Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary.

Authors:  H Haddad; D Isaac; J F Legare; P Pflugfelder; P Hendry; M Chan; B Cantin; N Giannetti; S Zieroth; M White; W Warnica; K Doucette; V Rao; A Dipchand; M Cantarovich; W Kostuk; R Cecere; E Charbonneau; H Ross; N Poirier
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

Review 3.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Antibody induction therapy in adult kidney transplantation: A controversy continues.

Authors:  Kanwaljit K Chouhan; Rubin Zhang
Journal:  World J Transplant       Date:  2012-04-24

5.  Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.

Authors:  L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

6.  Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.

Authors:  Camila Macedo; John T Walters; Elizabeth A Orkis; Kumiko Isse; Beth D Elinoff; Sheila P Fedorek; John M McMichael; Geetha Chalasani; Parmjeet Randhawa; Anthony J Demetris; Adriana Zeevi; Henkie Tan; Ron Shapiro; Doug Landsittel; Fadi G Lakkis; Diana Metes
Journal:  Transplantation       Date:  2012-04-27       Impact factor: 4.939

Review 7.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

8.  Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells.

Authors:  S C Wood; G Lu; B E Burrell; D K Bishop
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

9.  Clinical tolerance 2008.

Authors:  Allan D Kirk
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

Review 10.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.